secwatch.observer — SEC 8-K summary
======================================

Issuer:     Caribou Biosciences, Inc. (CRBU)
CIK:        0001619856
Form:       8-K
Filed at:   2022-11-21T23:59:59+00:00
Accession:  0001619856-22-000025
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Caribou Biosciences receives FDA IND clearance for CB-011, allogeneic anti-BCMA CAR-T therapy for multiple myeloma
--------------------------------------------------------------------------------

- CB-011 is a genome-edited allogeneic anti-BCMA CAR-T cell therapy with immune cloaking.
- CaMMouflage Phase 1 trial is an open-label, multicenter study evaluating CB-011 in relapsed/refractory multiple myeloma.
- Patient enrollment at dose level 1 (50x10^6 CAR-T cells) expected to begin in early 2023.
- CB-011 uses Cas12a chRDNA edits: anti-BCMA CAR insertion, TRAC KO, and B2M-HLA-E fusion for immune cloaking.
- This is Caribou's second allogeneic CAR-T to enter clinic, following CB-010 (anti-CD19, PD-1 KO) in ANTLER trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1619856/000161985622000025/0001619856-22-000025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1619856/000161985622000025/crbu-20221121.htm
  HTML page:      https://secwatch.observer/filing/0001619856-22-000025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer